Evicenter
MarkdownMedical informationP&T meetings
AD109 (aroxybutynin-atomoxetine)

Obstructive sleep apnea

Also known as Oxnimbi
Manufacturer
Apnimed
Launch
Not announced
Last updated
183 sources

Product information and disease descriptionPlace of product in therapyDisease description

Pathophysiology

9 evidence topics · 8 sources

Pharyngeal dilator muscle control: hypoglossal motor nucleus mechanisms targeted by AD109 (review; one author is an Apnimed employee)

“While anatomical vulnerability contributes to airway instability, a key determinant of OSA pathophysiology is the sleep-related reduction in upper airway neuromuscular activity that occurs at the wake–sleep transition.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Nonanatomical causes contribute to OSA in approximately 70% of patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“This endogenous noradrenergic excitation at the HMN is present in wakefulness, reduced in non-REM (NREM) sleep, and further reduced in REM sleep.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Upper airway dilator muscle activity decreases during sleep due to withdrawal of excitatory drive, including noradrenergic input, in rapid eye movement (REM) and non-REM (NREM) sleep, and recruitment of inhibitory muscarinic–GIRK (G-protein–coupled inwardly rectifying potassium) mechanisms in REM sleep at upper airway motor nuclei.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“AD109 combines norepinephrine reuptake inhibition (atomoxetine) to restore excitatory drive and antimuscarinic activity (aroxybutynin) to reduce inhibition, thereby stabilizing upper airway muscle tone and improving airway patency.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“R.L.H.’s laboratory received an unrestricted grant in September 2024 from Apnimed, Inc. to support future research in obstructive sleep apnea (OSA) pharmacotherapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“L.T.-M. is an Apnimed employee and is co-inventor of intellectual property for pharmacological therapy of OSA via the Brigham and Women’s Hospital.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote